-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, O8iqCLZd+CDlZ2eAOY1FZJG2kTEgTxjXc3LXfXbM4EOIVrpHobXlJcRTbDxsf1b1 znHgCeDH3S8xAy2yg9LJVA== 0000875320-08-000088.txt : 20081119 0000875320-08-000088.hdr.sgml : 20081119 20081119162614 ACCESSION NUMBER: 0000875320-08-000088 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20081118 FILED AS OF DATE: 20081119 DATE AS OF CHANGE: 20081119 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6165776000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sachdev Amit CENTRAL INDEX KEY: 0001406338 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 081201299 BUSINESS ADDRESS: BUSINESS PHONE: 617-444-6100 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml PRIMARY DOCUMENT X0303 4 2008-11-18 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001406338 Sachdev Amit C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE MA 02139 0 1 0 0 SVP, Public Policy,Gov Affairs Common Stock 2008-11-18 4 S 0 791 26.20 D 28166 D Common Stock 77 I 401(k) Transaction made pursuant to Mr. Sachdev's company approved trading plan established under Rule 10b5-1. Open market sales reported on this line occurred at a wieghted average price of $26.20 (range $25.75 to $26.53). Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Valerie L. Andrews, Attorney-In-Fact 2008-11-19 -----END PRIVACY-ENHANCED MESSAGE-----